Moffitt logo

Articles related to Lymphoma

Moffitt Cancer Center Earns Blue Distinction® Specialty Care Designation for Cellular Immunotherapy – CAR-T

Hospital recognized for quality, safety and improved health outcomes in delivering therapy Read More


Malignant Hematology ASCO Highlights

Moffitt’s Malignant Hematology physicians and scientists were proud to share and present their research findings at American Society of Clinical Oncology (ASCO 2022) Read More

Researchers Pinpoint Why Lymphoma Patients May Become Resistant to Specific Therapy, Identify Strategy to Overcome It

Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas Read More

New Study Highlights CAR T-cell Therapy Success for Lymphoma When Used as Standard of Care

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data Read More

Moffitt Researchers Identify New Target to Reduce Risk of Graft-Versus-Host Disease

JAK2 inhibitors minimize disease while maintaining antitumor response Read More


Moffitt’s Top Research Developments of 2017: CAR T Therapy Tested, Commercially Available at Moffitt

The first one on the list of Moffitt's top research developments for 2017 is the FDA approval of CAR T therapy for certain aggressive types of adult lymphoma. Read More

New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

New ZUMA-1 trial data published in The New England Journal of Medicine report long-term measurable remission rates 15 months following treatment with Yescarta™ Read More

Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy

Yescarta™ for Non-Hodgkin Lymphoma Launches Global Commercial Use for Breakthrough Immunotherapy Treatment Read More


Infographic: How CAR T Therapy Works to Fight Cancer

CAR T therapy, a groundbreaking new treatment, utilizes the body’s own immune system to fight cancer. Read More


What is CAR T Therapy?

Dr. Frederick Locke, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, answers some frequently asked questions about CAR T cell therapy. Read More


CAR T Cancer Therapy a ‘Huge Breakthrough’ for Patients with Lymphoma

Moffitt patients with an aggressive type of lymphoma were among the first to benefit in clinical trials of a groundbreaking therapy. Read More


September Is Blood Cancer Awareness Month – What You Need to Know

The U.S. Congress has designated September as Blood Cancer Awareness Month. Moffitt Cancer Center is pleased to join in this effort as a way to educate the general public and provide support, strength and hope to individuals who are affected by blood cancer. Read More


September Is Leukemia & Lymphoma Awareness Month

Approximately every four minutes, someone in the United States is diagnosed with leukemia, lymphoma or another type of cancer that affects the blood cells, bone marrow or lymphatic system. Read More